Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD011749. DOI: 10.1002/14651858.CD011749.pub2.
New review from the Cochrane Library.
Although delirium is typically an acute reversible cognitive impairment, its presence is associated with devastating impact on both short‐term and long‐term outcomes for critically ill patients. Advances in our understanding of the negative impact of delirium on patient outcomes have prompted trials evaluating multiple pharmacological interventions. However, considerable uncertainty surrounds the relative benefits and safety of available pharmacological interventions for this population.
"... did not find that any drug improved the duration of coma, length of stay, long‐term cognitive outcomes, or death"
"Dexmedetomidine was ranked most effective in reducing delirium duration, followed by atypical antipsychotics. However, network meta‐analysis of delirium duration failed to rule out the possibility of no difference for all six drug classes compared to placebo."